Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$54.87

-2.94 (-5.09%)

13:45
01/08/18
01/08
13:45
01/08/18
13:45

Sarepta sees 2018 Exondys 51 revenue $295M-$305M

The consensus estimate for total company revenue is $301.39M. The company said, "In 2017, we set the stage by successfully launching our first therapy, entering into important collaborations and ensuring we have ample resources to invest in our impressive pipeline. In 2018, we are accelerating our plans, moving 16 programs through various stages of development, and planning for multiple milestones and inflection points. And we are doing all of this to serve our lofty but achievable aspiration: to improve and extend the lives of the thousands of children suffering from DMD, expand our platform to other rare diseases, and in so doing, to become one of the most important global leaders in precision genetic medicine to reduce human suffering and treat disease."

  • 08

    Jan

SRPT Sarepta
$54.87

-2.94 (-5.09%)

12/18/17
MSCO
12/18/17
NO CHANGE
MSCO
Morgan Stanley sees opportunities in biotech amid 'limited' investor conviction
With clinical catalysts in large-cap Biotechnology limited to only five key Phase III readouts - three of which are from Alexion (ALXN) - investors are describing their 2018 picks in the space as the "least worst" of the group, according to Morgan Stanley analyst Matthew Harrison. However, he believes this lack of conviction creates real opportunity for outsized moves in 2018, with Amgen (AMGN) identified by Harrison as the biggest potential beneficiary of M&A given "its likely newfound access" to about $39B in offshore cash. Other biotech names the analyst highlights on the up side include Biogen (BIIB), BioMarin (BMRN), Biohaven (BHVN) and Sarepta (SRPT). Meanwhile, Harrison highlights his concerns about potential downside for BioVerativ (BIVV) and Innoviva (INVA), on both of which he keeps Underweight ratings.
12/27/17
OPCO
12/27/17
NO CHANGE
Target $76
OPCO
Outperform
Oppenheimer bullish on Sarepta into 2018
Oppenheimer analyst Hartaj Singh highlights Sarepta as a key SMID-cap pick in his coverage universe. The analyst believes Sarepta enters 2018 firing on all commercial and clinical cylinders with new CEO D. Ingram bringing a strategic and tactical focus to the company. While competitive intensity in Duchenne muscular dystrophy is starting to build, Singh thinks the competitive landscape is still a mish-mash of approaches, most of which are still in early/mid-stage development. He does not see any meaningful competition to Sarepta's DMD franchise for another 3-5 years. The analyst reiterates an Outperform rating and $76 price target on the shares.
01/03/18
JANY
01/03/18
INITIATION
Target $75
JANY
Buy
Sarepta initiated with a Buy at Janney Capital
Janney analyst Yun Zhong initiated Sarepta with a Buy rating and a $75 price target.
01/04/18
RHCO
01/04/18
INITIATION
Target $24
RHCO
Buy
Summit Therapeutics initiated with a Buy at SunTrust
SunTrust analyst Edward Nash initiated Summit Therapeutics (SMMT) with a Buy rating and a price target of $24. Nash says the company's ezutromid drug has the potential to address all 50K cases of Duchenne muscular dystrophy in the developed world, expecting the key interim data announced this quarter to be strong. The analyst notes that DMD remains a "high profile orphan disease", and only Sarepta's (SRPT) Exondys 51 treatment address about 13% of its patients.

TODAY'S FREE FLY STORIES

PG

Procter & Gamble

09:19
01/23/18
01/23
09:19
01/23/18
09:19
Hot Stocks
Procter & Gamble says commodity costs have moved up this year »

Says seeing some growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

PXD

Pioneer Natural

09:19
01/23/18
01/23
09:19
01/23/18
09:19
Recommendations
Pioneer Natural analyst commentary  »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

TYL

Tyler Technologies

09:18
01/23/18
01/23
09:18
01/23/18
09:18
Hot Stocks
Tyler Technologies selected by Orlando, Florida for public safety solution »

Tyler Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PE

Parsley Energy

09:18
01/23/18
01/23
09:18
01/23/18
09:18
Recommendations
Parsley Energy analyst commentary  »

Parsley Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 15

    May

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
01/23/18
01/23
09:18
01/23/18
09:18
Options
Overnight activity included 92 trades in SPX and 25 trades in VIX »

92 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

, LOGI

Logitech

$37.58

0.25 (0.67%)

09:17
01/23/18
01/23
09:17
01/23/18
09:17
Hot Stocks
On The Fly: Pre-market Movers »

UP AFTER EARNINGS:…

VZ

Verizon

LOGI

Logitech

$37.58

0.25 (0.67%)

JNJ

Johnson & Johnson

NFLX

Netflix

$227.58

7.12 (3.23%)

HBAN

Huntington Bancshares

$16.03

0.22 (1.39%)

KMB

Kimberly-Clark

RMD

ResMed

AMTD

TD Ameritrade

$55.88

0.71 (1.29%)

ATI

Allegheny Technologies

TSLA

Tesla

$351.56

1.54 (0.44%)

AAPL

Apple

$177.00

-1.46 (-0.82%)

PG

Procter & Gamble

ADMS

Adamas Pharmaceuticals

$40.79

2.6 (6.81%)

GPRO

GoPro

$6.30

0.01 (0.16%)

TWTR

Twitter

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 30

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 08

    Feb

  • 16

    Feb

  • 16

    Feb

  • 28

    Feb

  • 08

    Mar

  • 24

    Jan

NBL

Noble Energy

09:16
01/23/18
01/23
09:16
01/23/18
09:16
Recommendations
Noble Energy analyst commentary  »

Noble Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

JNJ

Johnson & Johnson

09:16
01/23/18
01/23
09:16
01/23/18
09:16
Hot Stocks
Johnson & Johnson sees apalutamide approval in 2018 »

Johnson & Johnson CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

ABEO

Abeona Therapeutics

$14.85

0.25 (1.71%)

09:16
01/23/18
01/23
09:16
01/23/18
09:16
Initiation
Abeona Therapeutics initiated  »

Abeona Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

EOG

EOG Resources

09:15
01/23/18
01/23
09:15
01/23/18
09:15
Recommendations
EOG Resources analyst commentary  »

EOG Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

FANG

Diamondback Energy

$132.21

4.64 (3.64%)

09:13
01/23/18
01/23
09:13
01/23/18
09:13
Recommendations
Diamondback Energy analyst commentary  »

Diamondback Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

09:13
01/23/18
01/23
09:13
01/23/18
09:13
Hot Stocks
Twitter drops as COO Anthony Noto resigns to become SoFi CEO »

Shares of Twitter (TWTR)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

AMRN

Amarin

$4.04

0.07 (1.76%)

09:12
01/23/18
01/23
09:12
01/23/18
09:12
Recommendations
Amarin analyst commentary  »

Amarin shares have room…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVN

Devon Energy

09:12
01/23/18
01/23
09:12
01/23/18
09:12
Recommendations
Devon Energy analyst commentary  »

Devon Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

TWTR

Twitter

09:12
01/23/18
01/23
09:12
01/23/18
09:12
Technical Analysis
Technical Take: Twitter drops on departure of COO Anthony Noto »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

CLR

Continental Resources

09:11
01/23/18
01/23
09:11
01/23/18
09:11
Recommendations
Continental Resources analyst commentary  »

Continental Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:10
01/23/18
01/23
09:10
01/23/18
09:10
Recommendations
Halliburton analyst commentary  »

Halliburton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CXO

Concho Resources

$160.41

4.22 (2.70%)

09:10
01/23/18
01/23
09:10
01/23/18
09:10
Recommendations
Concho Resources analyst commentary  »

Concho Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

09:09
01/23/18
01/23
09:09
01/23/18
09:09
Technical Analysis
Technical Take: Verizon trades higher after results »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

ANAB

AnaptysBio

$114.78

-0.135 (-0.12%)

09:08
01/23/18
01/23
09:08
01/23/18
09:08
Recommendations
AnaptysBio analyst commentary  »

AnaptysBio price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XEC

Cimarex Energy

$126.80

2.76 (2.23%)

09:08
01/23/18
01/23
09:08
01/23/18
09:08
Recommendations
Cimarex Energy analyst commentary  »

Cimarex Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 15

    Feb

DGX

Quest Diagnostics

$103.57

0.51 (0.49%)

09:08
01/23/18
01/23
09:08
01/23/18
09:08
Hot Stocks
Quest Diagnostics to acquire MedXM for undisclosed amount »

Quest Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

09:07
01/23/18
01/23
09:07
01/23/18
09:07
Hot Stocks
Breaking Hot Stocks news story on Verizon »

Verizon says FY18 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

SLB

Schlumberger

$79.79

3.37 (4.41%)

09:06
01/23/18
01/23
09:06
01/23/18
09:06
Recommendations
Schlumberger analyst commentary  »

Schlumberger price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$60.72

2.52 (4.33%)

09:06
01/23/18
01/23
09:06
01/23/18
09:06
Recommendations
Anadarko analyst commentary  »

Anadarko price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.